Is Cannabis the New Cool for Autism?

Nima Derakhshan; Zahra Hooshanginezhad

doi:10.1055/s-0037-1605582

Journal of Pediatric Neurology, Table of Contents

Journal of Pediatric Neurology 2017; 15(04): 187-190
DOI: 10.1055/s-0037-1605582

Letter to the Editor

Georg Thieme Verlag KG Stuttgart · New York

Is Cannabis the New Cool for Autism?

Nima Derakhshan

¹Department of Neurosurgery, Shiraz University of Medical Sciences, Shiraz, Iran

²Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

,

Zahra Hooshanginezhad

²Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

› Author Affiliations

Abstract

Full Text

References

References
1 Anderson CL, DeMarse TB, Febo M, Johnson CR, Earnest V, Carney PR. Cannabidiol for the treatment of drug-resistant epilepsy in children: current state of research. J Pediatr Neurol 2017; 15 (04) 143-150
2 Ghanizadeh A, Derakhshan N. N-acetylcysteine for treatment of autism, a case report. J Res Med Sci 2012; 17 (10) 985-987
3 Brigida AL, Schultz S, Cascone M, Antonucci N, Siniscalco D. Endocannabinod signal dysregulation in autism spectrum disorders: a correlation link between inflammatory state and neuro-immune alterations. Int J Mol Sci 2017; 18 (07) 1425
4 Siniscalco D, Sapone A, Giordano C. , et al. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders. J Autism Dev Disord 2013; 43 (11) 2686-2695
5 Utomo WK, de Vries M, Braat H. , et al. Modulation of human peripheral blood mononuclear cell signaling by medicinal cannabinoids. Front Mol Neurosci 2017; 10: 14
6 Zimmerman AW, Jyonouchi H, Comi AM. , et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 2005; 33 (03) 195-201
7 Al-Ayadhi LY. Pro-inflammatory cytokines in autistic children in central Saudi Arabia. Neurosciences (Riyadh) 2005; 10 (02) 155-158
8 Ricci S, Businaro R, Ippoliti F. , et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox Res 2013; 24 (04) 491-501
9 Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun 2011; 25 (01) 40-45
10 Rajesh M, Mukhopadhyay P, Bátkai S. , et al. CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293 (04) H2210-H2218
11 Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9 (06) 418-428
12 Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav Immun 2005; 19 (06) 493-499
13 Rosas-Ballina M, Olofsson PS, Ochani M. , et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334 (6052): 98-101
14 Derakhshan N. Vagal nerve stimulation for the treatment of autism. Ment Illn 2015; 7 (01) 5788
15 Levy ML, Levy KM, Hoff D. , et al. Vagus nerve stimulation therapy in patients with autism spectrum disorder and intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. J Neurosurg Pediatr 2010; 5 (06) 595-602
16 Sala M, Braida D, Lentini D. , et al. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 2011; 69 (09) 875-882
17 Wainwright A, Rutter AR, Seabrook GR, Reilly K, Oliver KR. Discrete expression of TRPV2 within the hypothalamo-neurohypophysial system: implications for regulatory activity within the hypothalamic-pituitary-adrenal axis. J Comp Neurol 2004; 474 (01) 24-42
18 Caterina MJ, Leffler A, Malmberg AB. , et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000; 288 (5464): 306-313
19 Andari E, Duhamel JR, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A 2010; 107 (09) 4389-4394
20 Bou Khalil R. Would some cannabinoids ameliorate symptoms of autism?. Eur Child Adolesc Psychiatry 2012; 21 (04) 237-238
21 Wang CC, Lin HC, Chan YH, Gean PW, Yang YK, Chen PS. 5-HT1A-receptor agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model. Int J Neuropsychopharmacol 2013; 16 (09) 2027-2039
22 Sartim AG, Guimarães FS, Joca SR. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res 2016; 303: 218-227
23 Rohleder C, Müller JK, Lange B, Leweke FM. Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence. Front Pharmacol 2016; 7: 422
24 Wang H, Doering LC. Reversing autism by targeting downstream mTOR signaling. Front Cell Neurosci 2013; 7: 28
25 Renard J, Loureiro M, Rosen LG. , et al. Cannabidiol counteracts amphetamine-induced neuronal and behavioral sensitization of the mesolimbic dopamine pathway through a novel mTOR/p70S6 kinase signaling pathway. J Neurosci 2016; 36 (18) 5160-5169
26 Schwartz Y. Marijuana may be a miracle treatment for children with autism. Available at: https://www.usatoday.com/story/news/world/2017/04/25/marijuana-pot-treatment-children-autism-cannabis-oil/100381156/ . Published: April 25, 2017. Accessed July 13, 2017
27 Salari P, Abdollahi M. Ethics in pharmacy curriculum for undergraduate pharmacy students: a needs assessment study. Arch Iran Med 2017; 20 (01) 38-42